Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer.
Bischoff H, Bigot C, Moinard-Butot F, Pflumio C, Fischbach C, Kalish M, Kurtz JE, Pierard L, Demarchi M, Karouby D, Coliat P, Pivot X, Petit T, Cox DG, Goepp L, Bender L, Trensz P. Bischoff H, et al. Among authors: demarchi m. Breast Cancer Res Treat. 2023 Feb;198(1):23-29. doi: 10.1007/s10549-022-06844-5. Epub 2022 Dec 23. Breast Cancer Res Treat. 2023. PMID: 36562910
TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin® and US-Herceptin® in healthy male subjects.
Demarchi M, Coliat P, Mclendon K, Chung Shii Hii J, Feyaerts P, Ang F, Jaison L, Deforce F, Derde MP, Kim MJ, Park LS, Detappe A, Pivot X. Demarchi M, et al. Pharmacol Res Perspect. 2021 Aug;9(4):e00839. doi: 10.1002/prp2.839. Pharmacol Res Perspect. 2021. PMID: 34309241 Free PMC article. Clinical Trial.
A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.
Demarchi M, Coliat P, Barthelemy P, Schott R, BenAbdelghani M, Kim M, Hii JCS, Feyaerts P, Ang FRX, Derde MP, Deforce F, Petit T, Schwabe C, Wynne C, Park LS, Pivot X. Demarchi M, et al. PLoS One. 2021 Sep 23;16(9):e0248222. doi: 10.1371/journal.pone.0248222. eCollection 2021. PLoS One. 2021. PMID: 34555031 Free PMC article. Clinical Trial.
Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol.
Mallard J, Hucteau E, Schott R, Petit T, Demarchi M, Belletier C, Ben Abdelghani M, Carinato H, Chiappa P, Fischbach C, Kalish-Weindling M, Bousinière A, Dufour S, Favret F, Pivot X, Hureau TJ, Pagano AF. Mallard J, et al. Among authors: demarchi m. Front Oncol. 2020 Aug 7;10:1304. doi: 10.3389/fonc.2020.01304. eCollection 2020. Front Oncol. 2020. PMID: 32903594 Free PMC article.
Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.
Carinato H, Burgy M, Ferry R, Fischbach C, Kalish M, Guihard S, Brahimi Y, Flesch H, Bronner G, Schultz P, Frasie V, Thiéry A, Demarchi M, Petit T, Jung AC, Wagner P, Coliat P, Borel C. Carinato H, et al. Among authors: demarchi m. Front Oncol. 2021 Oct 27;11:714551. doi: 10.3389/fonc.2021.714551. eCollection 2021. Front Oncol. 2021. PMID: 34778031 Free PMC article.
Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients.
Paquette B, Kalbacher E, Mercier F, Lakkis Z, Doussot A, Turco C, Caputo E, Pili-Floury S, Royer B, Mansi L, Delroeux D, Demarchi M, Pivot X, Chauffert B, Clement E, Heyd B. Paquette B, et al. Among authors: demarchi m. Ann Surg Oncol. 2022 May;29(5):3322-3334. doi: 10.1245/s10434-021-11211-7. Epub 2022 Jan 7. Ann Surg Oncol. 2022. PMID: 34994906
Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.
Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, Pivot X, Godet Y, Degano SV, Borg C. Dobi E, et al. Among authors: demarchi m. Clin Colorectal Cancer. 2013 Mar;12(1):28-36. doi: 10.1016/j.clcc.2012.09.002. Epub 2012 Oct 17. Clin Colorectal Cancer. 2013. PMID: 23083634
127 results